104 results about "Death Receptors" patented technology

The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and/or 199V; preferably also 201R, 213W and 215D, and/or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same.

The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-κB, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules.

Disclosed in the present invention are a mouse monoclonal antibody for antagonizing and inhibiting the binding of a programmed death-1 (PD-1) to the ligand thereof, and the heavy chain variable region and light chain variable region amino acid sequences thereof. Also disclosed in the present invention is a DNA molecule nucleotide sequence encoding the heavy chain variable region and light chain variable region of the antibody. Also disclosed in the present invention are a method for preparing a human-mouse chimeric antibody of the antibody and derivatives thereof, and the use thereof in PD-1 protein detection.

Compositions containing epidithiodioxopiprazines and methods of their use are provided. Epidithiodioxopiprazines can be isolated from natural resources or synthesized de novo. Moreover, epidithiodioxopiprazines, including Verticillin A, are shown to effectively sensitize multiple types of tumor cells to TRAIL-induced apoptosis. In addition, epidithiodioxopiprazines, including Verticillin A, are shown to effectively overcome cancer cell resistance to existing drugs (i.e. Etoposide, Cisplatin, 5-FU and Doxorubicin). Therefore, compositions and methods are provided for use in sensitizing target cancer cells to death receptor- and other anticancer drugs-induced apoptosis. Methods of treating cancer in a subject in need thereof are also provided.

Methods of identifying death receptor sensitizing compounds and methods of using death receptor sensitizing compounds are provided.

Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.

The invention relates to sDR5-Fc recombinant protein (ZJ501-5) with an amino acid sequence shown as SEQ ID NO: 2 and a gene shown as SEQ ID NO: 1 of the recombinant protein, and meanwhile, the invention discloses an application of the sDR5-Fc recombinant protein and the gene thereof in preparing medicines for treating immune liver diseases. In addition, bioactivity of the sDR5-Fc protein in vitro is 3 times higher than that of an sDR5-Fc product from R&D systems Company, the proportion of an N terminal splice variant is just about 1% and the sDR5-Fc protein is high in protein drug stability; and the sDR5-Fc protein provided by the invention, which can significantly improve a survival rate of mice having Con A induced acute autoimmune hepatitis, has a potential application value for treating autoimmune hepatitis in human being.

The invention belongs to the technical field of genetic engineering drugs, and discloses a double-target-spot fusion protein capable of enhancing the TRAIL antitumor activity. The cDNA sequence of the overall-length fusion gene sequence 1 is shown in SEQ ID NO1; the coding amino acid sequence of the overall-length fusion gene sequence 1 is shown in SEQ ID NO2; the coding cDNA sequence of the overall-length fusion gene sequence 2 is shown in SEQ ID NO4; and the coding amino acid sequence of the overall-length fusion gene sequence 2 is shown in SEQ ID NO5. In comparison with the prokaryotic expression carrier of separate TRAIL protein soluble fragment coding cDNA sequence, the fusion protein of the prokaryotic expression carrier has higher soluble expression, and the recycling and purifying efficiency of the fusion protein is higher; and the in-vitro biological activity analysis indicates that the fusion protein can activate death receptors on the cell membrane and inhibit expression of an XIAP gene in the cell plasma, enhance the activity of inducing tumor cell apoptosis through the double-target-spot function in apoptotic pathway and ensure stronger antitumor effect.

The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.

The invention discloses stem cells for specifically expressing a programmed death receptor 1 (PD-1), and particularly relates to the stem cells from an organic cavity. The stem cells comprise but notlimited to dental pulp stem cells, gingival mesenchymal steam cells (GMSCs), periodontal ligament stem cells (PDLSCs), stem cells of apical papilla (SCAPs) and dental follicle stem cells (DFSCs) or any combination thereof, and preferably comprise stem cells from human exfoliated deciduous teeth (SHED) and/or dental pulp mesenchymal stem cells for permanent teeth (DPSC); the stem cells also includemesenchymal stem cells from other tissues, which do not express the PD-1 at first and express the PD-1 after being modified by CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), suchas PD-1 plus bone mesenchymal stem cells (BMMSC) modified by the CRISPR. The invention further discloses an identifying and separating method for the stem cells for specifically expressing the PD-1,a method for preparing the PD-1 plus mesenchymal stem cells modified by the CRISPR as well as application of the mesenchymal stem cells for expressing the PD-1, disclosed by the invention, in tissue regeneration, pain relief and treatment of chronic pain and a series of diseases.

The invention provides an antibody in an extracellular region of a death receptor-5 of a tumor necrosis factor-related apoptosis inducing ligand. By a death receptor-5 agitated polyvalent antibody, a single-chain antibody of the death receptor-5 forms a polyvalent antibody through an oligomerization structural domain, and the amino acid sequence is shown as SEQIDNO.1. The single-chain antibody of the death receptor-5 forms a tetravalent antibody through a p53 structural domain, and the amino acid sequence is shown as SEQIDNO.2. After multimerization, the antibody can induce apoptosis of tumor cells, and is nontoxic to normal cells. The invention also provides an application of the death receptor-5 agitated polyvalent antibody in preparation of anti-tumor medicines.

A bispecific antibody format devoid of an active Fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on B-cells, for use in the treatment or prevention of B cell mediated autoimmune diseases.

Cyclosporin A has been discovered to sensitize cancers resistant to TNF-family death receptors such as TRAIL and Fas to ligand-mediated apoptosis. Therefore, compositions that include cyclosporin A are useful in treating such cancers.

The invention belongs to the technical field of medicines, in particular relates to a physalin A extracting process and medical application thereof, in particular relates to a novel application of physalin A in preparation of an anti-tumor dug and in particular relates to the use of physalin A in treatment of human fibrosarcoma and human malignant melanoma. After process optimization, the extracting rate of physalin A is 0.2133%. Physalin A can be used for inhibiting the growth of various tumor cells, particularly has obvious inhibiting action on the growth of the human fibrosarcoma and human malignant melanoma, but does not inhibit the activities of the human normal cells obviously. The mechanism is that the downstream caspase family-associated protein is activated by activating Fas death receptors, so that the tumor cells are induced to generate apoptosis. Meanwhile, the physalin A can be used for inducing the tumor cells to generate autophagy for achieving autophagy antagonism apoptosis in the HT1080 and the A375-S2 cells; and the p53 protein and the MAPK (Mitogen-Activated Protein Kinase)-familty p38 protein have a key regulation effect. The physalin A can be used for preparing a digestive tract dosage form or a non-digestive tract dosage form, which can be used for treating tumors including the human fibrosarcoma and human malignant melanoma.

The invention belongs to the field of biotechnology, and in particular relates to a method for regulating expression, quantity and activity of a heat shock protein 70 and application thereof. The method provided by the invention can also regulate tumor tissue, activity of a transcription factor NF-kB, expression and activity of a death receptor DR4 and DR5, phosphorylation and activity of JNK and c-Jun, expression and activity of a p53 protein, expression and proapoptotic activity of proapoptotic molecules Bax, Bid, t-Bid, capsase 3, capsase 8 and capsase 9, and expression and activity of c-FLIP and Bcl-2, and promote apoptosis of tumor tissues and cells. The invention also relates to application of the above method to preparation of drugs cooperatively applied with cell apoptosis induced drug.

The invention provides a pharmaceutical preparation containing a cell programmed death acceptor 1 monoclonal antibody. The pharmaceutical preparation comprises ingredients: a PD-1 monoclonal antibody,a citric acid-sodium citrate buffer solution, a protein protectant, a surfactant and an isotonicity regulator. According to the pharmaceutical preparation, proven by a longest-4-week accelerated experiment at a temperature of 40 DEG C, major detection indexes, i.e., testing equivalent standards such as appearance, concentration, turbidity (A350), pH value, osmotic pressure and purity are all freeof obvious changes, and good stability is shown.

The invention discloses a nucleic acid aptamer of a programmed death receptor-ligand 1 (PD-L1) and application of the nucleic acid aptamer, and relates to a nucleic acid. The nucleic acid aptamer withhigh specific recognition on PD-L1 and high affinity combination force on PD-L1 is provided. The nucleic acid aptamer can be screened and prepared by means of a protein SELEX method based on agarosemicrobead separation-flow cytometry analysis. The nucleic acid aptamer has the advantages that G basic groups are abundant, a stem-loop structure is provided, synthesis and marking are easy, the costis low, the stability is high, and non-immunogenicity is excellent; the nucleic acid aptamer is utilized to achieve the specific recognition of PD-L1 proteins, tumor cell lines of PD-L1 expression proteins and exudates of the PD-L1 expression proteins excreted by the tumor cell lines, the application of the nucleic acid aptamer in the field of biochemical analysis and detection is verified, the nucleic acid aptamer is expected to be used as a molecular recognition tool for detecting the expression level of PD-L1 and applied to precise prediction and dynamic monitoring of the treatment effect of PD-1/PD-L1 inhibitors in the field of clinical medical tumor immunity research.

The invention discloses a chemiluminescence kit for rapid diagnosis of uterine sarcoma in early and middle stages. Tumor markers comprise CD10, a death receptor and a growth differentiation factor-15.The kit comprises a tumor marker standard, a tumor marker monoclonal capture antibody-coated microwell plate, a horseradish peroxidase or alkaline phosphatase-labeled tumor marker monoclonal detection antibody, a chemiluminescent substrate solution and a concentrated scrubbing solution. The chemiluminescence kit has high sensitivity of 70% or more and strong accuracy of 70% or more, is low in cost and reduces operation steps and detection error.